126 related articles for article (PubMed ID: 26546964)
21. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
22. Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia.
Shah R; Polen-De C; McGree M; Fought A; Kumar A
Curr Oncol; 2023 Oct; 30(11):9501-9513. PubMed ID: 37999108
[TBL] [Abstract][Full Text] [Related]
23. The use of intraperitoneal chemotherapy for advanced ovarian cancer - The experience of a tertiary referral centre.
Foster L; Girgis C; Kirby A; Harnett P; Brand A
Aust N Z J Obstet Gynaecol; 2023 Nov; ():. PubMed ID: 37994114
[TBL] [Abstract][Full Text] [Related]
24. The Role of Intraperitoneal Carboplatin as Consalidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review.
Mousavi A; Karimi-Zarchi M; Behtash N; Modares-Gilani M; Mokhtari-Gorgani M; Mehrdad N; Rouhi M; Anari PY
Int J Biomed Sci; 2016 Dec; 12(4):120-124. PubMed ID: 28190981
[TBL] [Abstract][Full Text] [Related]
25. Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics-A Review.
Stankovic JSK; Selakovic D; Mihailovic V; Rosic G
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092125
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin-Induced Hematuria With Obstructive Acute Kidney Injury.
Nallathambi N; Chinnadurai A; S Y
Cureus; 2024 Apr; 16(4):e58931. PubMed ID: 38800179
[TBL] [Abstract][Full Text] [Related]
27. Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation.
Muramatsu T; Shinozuka T; Hirasawa T; Tsukada H; Maeda H; Miyamoto T; Murakami M; Kajiwara H; Yasuda M; Osamura RY; Mikami M
Acta Histochem Cytochem; 2006 Jul; 39(3):61-7. PubMed ID: 17327925
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N; Lawrie TA
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD005340. PubMed ID: 26755441
[TBL] [Abstract][Full Text] [Related]
29. Second-line treatment of metastatic gastric cancer: Current options and future directions.
Kanagavel D; Fedyanin M; Tryakin A; Tjulandin S
World J Gastroenterol; 2015 Nov; 21(41):11621-35. PubMed ID: 26556991
[TBL] [Abstract][Full Text] [Related]
30. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
Hotouras A; Desai D; Bhan C; Murphy J; Lampe B; Sugarbaker PH
Int J Gynecol Cancer; 2016 May; 26(4):661-70. PubMed ID: 26844612
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy of ovarian cancer in elderly patients.
Troso-Sandoval TA; Lichtman SM
Cancer Biol Med; 2015 Dec; 12(4):292-301. PubMed ID: 26779366
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
33. [INTRAVENOUS CHEMOTHERAPY VERSUS INTRAPERITONEAL CHEMOTHERAPY IN ADVANCED OVARIAN CANCER: UPDATE ON THE SITUATION WORLDWIDE AND IN ISRAEL].
Binyamin S; Segev Y; Auslender R; Bitterman A; Lavie O
Harefuah; 2015 Sep; 154(9):594-8, 607, 606. PubMed ID: 26665753
[TBL] [Abstract][Full Text] [Related]
34. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
Ye H; Tanenbaum LM; Na YJ; Mantzavinou A; Fulci G; Del Carmen MG; Birrer MJ; Cima MJ
J Control Release; 2015 Dec; 220(Pt A):358-367. PubMed ID: 26548976
[TBL] [Abstract][Full Text] [Related]
35. Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure ‒ assessment in a novel porcine model.
Petersen EK; Bue M; Harlev C; Jørgensen AR; Schmedes A; Hanberg P; Petersen LK; Stilling M
Pleura Peritoneum; 2022 Sep; 7(3):117-125. PubMed ID: 36159212
[TBL] [Abstract][Full Text] [Related]
36. Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences.
Shen Y; Tang S; Xu J; Xie X; Chen Z
Front Med (Lausanne); 2022; 9():846352. PubMed ID: 35372416
[TBL] [Abstract][Full Text] [Related]
37. Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.
O'Dwyer J; O'Cearbhaill RE; Wylie R; O'Mahony S; O'Dwyer M; Duffy GP; Dolan EB
Adv Ther (Weinh); 2020 Nov; 3(11):. PubMed ID: 33709016
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy.
Eoh KJ; Lee JY; Nam EJ; Kim S; Kim YT; Kim SW
J Korean Med Sci; 2017 Dec; 32(12):2021-2028. PubMed ID: 29115086
[TBL] [Abstract][Full Text] [Related]
40. Thinking outside the shunt-sterile CSF malabsorption in pilocytic astrocytomas: case series and review of the literature.
Johnson JA; O'Halloran PJ; Crimmins D; Caird J
Childs Nerv Syst; 2016 Nov; 32(11):2255-2260. PubMed ID: 27193012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
